This article was originally published on PharmaTimes http://www.pharmatimes.com/news/another_alzheimers_setback_as_amgen,_novartis_abandon_bace_inhibitor_trial_1294456

Sponsors concluded that the potential benefit for participants in the studies did not outweigh the risk.

Related Posts